Clinical Trial Update: Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intraarterial cetuximab (Erbitux) and bevacizumab for relapsed/refractory intracranial glioma in patients under 22; status terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Brain Stem Glioma
• Diffuse Intrinsic Pontine Glioma
• Fibrillary Astrocytoma
• Glioblastoma
• Glioma of Brainstem
• Mixed Oligodendroglioma Astrocytoma
• Pilomyxoid Astrocytoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERBITUX (cetuximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-08-09